Globe Newswire
TORONTO, May 23, 2024 (GLOBE NEWSWIRE) -- Fairfax Financial Holdings Limited (“Fairfax”) (TSX: FFH and FFH.U) regrettably announces that Ramaswamy Athappan, Chairman and Chief Executive Officer of Fairfax Asia Limited, has passed away.
Over the past 22 years, Mr. Athappan has been a driving force in developing Fairfax’s insurance operations in Southeast Asia. He made invaluable contributions to the success of Fairfax and Fairfax Asia over these years... (continue reading...)
VANCOUVER, British Columbia, May 23, 2024 (GLOBE NEWSWIRE) -- Imperial Metals Corporation (“Imperial” or the “Company”) (TSX: III) reports, in accordance with the policies of the Toronto Stock Exchange, that the nominees listed in the management information circular dated April 5, 2024, were elected as directors of the Company at the Company’s virtual Annual General Meeting of Shareholders held on May 22, 2024 (the "Meeting").
Results of the vote for the... (continue reading...)
New York, NY, May 23, 2024 (GLOBE NEWSWIRE) -- Optimum AI is set to revolutionize the Decentralized Finance (DeFi) landscape with its innovative text-based trading platform, now accessible through popular messaging apps WhatsApp and Telegram. This groundbreaking approach aims to simplify DeFi participation by allowing users to execute trades, bridge assets across blockchains, and access contract audits using simple text commands.
Optimumai tech
... (continue reading...)SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, May 23, 2024 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced that it will present encouraging preliminary data of AN0025 in combination with definitive chemoradiotherapy (dCRT) in unresectable locally advanced or locally recurrent esophageal cancer... (continue reading...)
NEW YORK, May 23, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Direct Digital Holdings, Inc. (“Direct Digital” or the “Company”) (NASDAQ: DRCT) in the United States District Court for the Southern District of Texas on behalf of all persons and entities who purchased or otherwise acquired Direct Digital common stock between April 17, 2023... (continue reading...)
More Globe Newswire
View Older Stories-
HUTCHMED Highlights Presentations at the 2024 ASCO Annual Meeting
-
Tornado Global Hydrovacs Reports First Quarter 2024 Results
-
Jamieson Wellness Inc. Announces Voting Results from 2024 Annual Meeting of Shareholders
-
LexinFintech Holdings Ltd. Reports First Quarter 2024 Unaudited Financial Results
-
Restaurants Canada Expresses Concern as BC Restaurants Brace for Chicken Price Surge
-
AXTI Stockholders: Robbins LLP Reminds AXTI Stockholders of Securities Fraud Class Action Against AXT, Inc.
-
Mediacom Communications Ready to Connect Customers in First Phase of 221-Mile Seminole County Fiber Network Buildout
-
Western Pacific Trust Company Announces Q1-2024 Results
-
The Dominican Republic and Purdue University Sign MOU to Drive Semiconductor Growth
-
Myriad Genetics Showcases New Research and Product Innovations Advancing Cancer Care at 2024 ASCO® Annual Meeting
-
Associa Recognized as a US Best Managed Company
-
Huize Holding Limited Reports First Quarter 2024 Unaudited Financial Results
-
Gildan Board of Directors Resigns
-
Acceleware Ltd. Reports First Quarter 2024 Financial and Operating Results
-
Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine receptor 8 (CCR8) Antibody, CHS-114, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeti
-
Parks! America, Inc. Announces Glass Lewis Recommends Parks! America Shareholders Vote “FOR” Each of the Director Nominees Recommended by the Board
-
CORRECTION – The Herzfeld Caribbean Basin Fund, Inc. Announces Distribution in Stock and Cash
-
Mountain America Credit Union Named Utah's Leading SBA Lender for Third Consecutive Year
-
Stockholder Alert: Robbins LLP Informs Investors that a Class Action has been filed Against Cambium Networks Corporation (CMBM)
-
3Daughters to Participate in Women’s Health Panel During the 2024 BIO International Convention in San Diego, CA, June 3-6
-
Elicio Therapeutics Announces Preliminary Data from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P in Patients with mKRAS-driven Solid Tumors at the 2024 ASCO Annual Meeting
-
Premier Health Reports 2024 Second Quarter Results
-
Titanium Transportation Group Declares Quarterly Dividend
-
ALT Stockholders: Robbins LLP Reminds ALT Stockholders of Securities Fraud Class Action Against Altimmune, Inc.
-
MTTR Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of Matterport to CoStar Group
-
MTTR Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of Matterport to CoStar Group
-
HRBR Stockholders: Robbins LLP Reminds HRBR Stockholders of Securities Fraud Class Action Against Harbor Diversified, Inc.
-
DOCS INVESTOR NEWS: ROSEN, TRUSTED NATIONAL TRIAL COUNSEL, Encourages Doximity, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – DOCS
-
Trailblazing Dragons' Den Star Named United Nations Association in Canada's 2024 Global Citizen Laureate
-
INTC Stockholders: Robbins LLP Reminds INTC Stockholders of Securities Fraud Class Action Against Intel Corporation
-
Fresh2 Group Ltd. Announces Receipt of a Delinquency Compliance Alert Notice from Nasdaq
-
Fresh2 Group Ltd. Announces Receipt of a Delinquency Compliance Alert Notice from Nasdaq
-
Kronos Bio to Present Clinical Update on Phase 1/2 Trial of KB-0742 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
-
SpringWorks Therapeutics Announces Data to be Presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
-
Special Olympics Florida and Orlando Health Announce Five-Year Partnership
-
Sensei Biotherapeutics Presents Promising Clinical Data from Phase 1 Dose Escalation Study of SNS-101
-
Ivy Brain Tumor Center announces Phase 0/2 clinical readout of niraparib indicating significant improvement in overall survival of newly diagnosed glioblastoma patients
-
G1 Therapeutics Announces Upcoming Presentation at the 2024 American Society of Clinical Oncology (ASCO) Meeting
-
Updated Phase 1 Clinical Data for SYS-6002 (CRB-701) to be presented at 2024 ASCO Annual Meeting
-
FibroGen Announces Presentation of Positive Interim Data from the Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer (m
-
NKGen Biotech Publishes Phase 1 Interim Analysis Results of SNK02 Allogeneic NK Cell Therapy in Advanced Solid Tumors at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
-
Cogent Biosciences Appoints Cole Pinnow as Chief Commercial Officer
-
BioAtla Presenting Phase 1 Evalstotug Clinical Trial Data Demonstrating Clinical Benefit at the Upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
-
Compass Therapeutics to Present Phase 1 Data for CTX-471, A Novel CD137 Agonist Antibody, Demonstrating Anti-Tumor Activity in Patients Who Have Progressed on Approved PD-1 or PD-L1 Inhibitors at the
-
I-Mab Announces Encouraging Phase 1 Clinical Data of PD-L1x4-1BB Bispecific Antibody Ragistomig at ASCO 2024
-
Elcora Announces Share Consolidation
-
Affimed Announces Positive Early Efficacy and Progression Free Survival Results of AFM24-102 Study in EGFR Wild-Type Non-Small Cell Lung Cancer at the Annual Meeting of the American Society of Clinica
-
Cullinan Therapeutics to Present First Data for CLN-619, a Novel Anti-MICA/B Antibody, in Combination with a Checkpoint Inhibitor and Updated Monotherapy Data at ASCO 2024
-
Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to be Reported at ASCO
-
Zentalis Pharmaceuticals to Present Promising Results from Phase 1 Trial of Azenosertib and Gemcitabine in Relapsed or Refractory Osteosarcoma at 2024 American Society of Clinical Oncology Annual Meet